219 related articles for article (PubMed ID: 21045757)
1. Guanfacine extended-release (intuniv) for ADHD.
Med Lett Drugs Ther; 2010 Oct; 52(1349):82-3. PubMed ID: 21045757
[No Abstract] [Full Text] [Related]
2. Guanfacine extended-release for attention-deficit/hyperactivity disorder (ADHD).
Sallee FR; Eaton K
Expert Opin Pharmacother; 2010 Oct; 11(15):2549-56. PubMed ID: 20831361
[TBL] [Abstract][Full Text] [Related]
3. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
Childress AC
Adv Ther; 2012 May; 29(5):385-400. PubMed ID: 22610723
[TBL] [Abstract][Full Text] [Related]
4. A case of excessive weight gain with guanfacine extended release: 9.53 kg in 4 weeks.
Khan MA; Jain G; Soltys SM; Takahashi A
J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):256-7. PubMed ID: 22537187
[No Abstract] [Full Text] [Related]
5. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
Hervas A; Huss M; Johnson M; McNicholas F; van Stralen J; Sreckovic S; Lyne A; Bloomfield R; Sikirica V; Robertson B
Eur Neuropsychopharmacol; 2014 Dec; 24(12):1861-72. PubMed ID: 25453486
[TBL] [Abstract][Full Text] [Related]
6. ▼Guanfacine for ADHD in children and adolescents.
Drug Ther Bull; 2016 May; 54(5):56-60. PubMed ID: 27173784
[TBL] [Abstract][Full Text] [Related]
7. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration.
Newcorn JH; Stein MA; Childress AC; Youcha S; White C; Enright G; Rubin J
J Am Acad Child Adolesc Psychiatry; 2013 Sep; 52(9):921-30. PubMed ID: 23972694
[TBL] [Abstract][Full Text] [Related]
8. Guanfacine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
Rizzo R; Martino D
Expert Rev Neurother; 2015 Apr; 15(4):347-54. PubMed ID: 25800130
[TBL] [Abstract][Full Text] [Related]
9. Guanfacine ER for the treatment of adolescent attention-deficit/hyperactivity disorder.
Bukstein OG; Head J
Expert Opin Pharmacother; 2012 Oct; 13(15):2207-13. PubMed ID: 22957772
[TBL] [Abstract][Full Text] [Related]
10. Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder.
Kollins SH; López FA; Vince BD; Turnbow JM; Farrand K; Lyne A; Wigal SB; Roth T
J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):111-20. PubMed ID: 21476931
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of guanfacine extended release in adolescents aged 13-17 years with attention-deficit/hyperactivity disorder.
Martin P; Satin L; Vince BD; Padilla AF; White C; Corcoran M; Stevenson A; Ermer J
Clin Pharmacol Drug Dev; 2014 Jul; 3(4):252-61. PubMed ID: 27128830
[TBL] [Abstract][Full Text] [Related]
12. Guanfacine extended-release: in attention deficit hyperactivity disorder.
Muir VJ; Perry CM
Drugs; 2010 Sep; 70(13):1693-702. PubMed ID: 20731476
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.
Sikirica V; Haim Erder M; Xie J; Macaulay D; Diener M; Hodgkins P; Wu EQ
Pharmacoeconomics; 2012 Aug; 30(8):e1-15. PubMed ID: 22788263
[TBL] [Abstract][Full Text] [Related]
14. Impact of a Step Therapy for Guanfacine Extended-Release on Medication Utilization and Health Care Expenditures Among Individuals Receiving Treatment for ADHD.
Suehs BT; Sikirica V; Mudumby P; Dufour R; Patel NC
J Manag Care Spec Pharm; 2015 Sep; 21(9):793-802, 802a-802i. PubMed ID: 26308226
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder.
Boellner SW; Pennick M; Fiske K; Lyne A; Shojaei A
Pharmacotherapy; 2007 Sep; 27(9):1253-62. PubMed ID: 17723079
[TBL] [Abstract][Full Text] [Related]
16. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the current data on guanfacine extended release for the treatment of ADHD in children and adolescents.
Childress A; Hoo-Cardiel A; Lang P
Expert Opin Pharmacother; 2020 Mar; 21(4):417-426. PubMed ID: 31971448
[No Abstract] [Full Text] [Related]
18. Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists.
Wigal SB; Chae S; Patel A; Steinberg-Epstein R
Semin Pediatr Neurol; 2010 Dec; 17(4):230-6. PubMed ID: 21183129
[TBL] [Abstract][Full Text] [Related]
19. Guanfacine extended release in the treatment of attention deficit hyperactivity disorder in children and adolescents.
Connor DF; Rubin J
Drugs Today (Barc); 2010 May; 46(5):299-314. PubMed ID: 20517532
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison.
Erder MH; Xie J; Signorovitch JE; Chen KS; Hodgkins P; Lu M; Wu EQ; Sikirica V
Appl Health Econ Health Policy; 2012 Nov; 10(6):381-95. PubMed ID: 23113551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
